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Current approaches to anti-viral therapy (AVT) in the setting of
liver transplantation are based on the use of pegylated interferon
in combination with ribavirin (PegIFN/RBV). Attempts to clear
HCV pretransplant have been successful in about 15–20% of the
patients with genotype 1 infection and about 20–35% with geno-
type 3 [1,2] Such patients usually have relatively lower MELD
scores (<18) than many other patients listed for transplant.
Despite this AVT is associated with an increased risk of serious
bacterial infections [3]. Sustained viral response (SVR) pretrans-
plant is associated with lack of viral recurrence post-transplant
[1,2] Early post-transplant AVT is not thought to be useful due
to lack of efﬁcacy and poor tolerability [4,5]. The commencement
of AVT is usually considered at about the 12-month mark based
on protocol biopsies. Patients with either F2 or F1 with signiﬁcant
portal inﬂammation (stage P to 2) are usually considered for
AVT6.-8. SVRs in the range of 20–30% for patients with HCV geno-
type 1 (G1) and 40–50% for patients with HCV G3 are obtained
[6–8]. SVR post-transplant has been linked to both donor and
recipient IL28 polymorphisms [9–11]. Achievement of SVR in
the post-transplant setting is associated with improved survival
compared to patients who do not achieve an SVR [6–8].
Given the importance of viral clearance in the pre and post-
transplant setting, such results have been thought to be some-
what unsatisfactory and the liver transplant community has been
eagerly awaiting new anti-HCV therapies.A brief summary of the new HCV therapies
Perhaps it is best to consider the new AVTs as ﬁrst, second, and
third ‘‘wave’’ therapies (Table 1). These new AVTs include direct
antiviral agents (DAAs). The ﬁrst DAA wave consists of therapy
with the NS3/4A protease inhibitors (P.Is) boceprevir or telaprevir
added to pegylated interferon and ribavirin [12–15]. National
registration bodies have recently approved these new agents.
They are administered 3 times per day and are aimed againstJournal of Hepatology 20
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increased from 45–50% to 60–70% for treatment naïve patients.
The second wave consists of replacing boceprevir and telapre-
vir with second generation NS3/4A protease, HCV polymerase or
NS5a inhibitors (summarized in [16]). These agents can be given
daily, sometimes have additional genotype speciﬁcity but may
also still have signiﬁcant side effect proﬁles [17–33]. The next
generation protease inhibitors in combination with PegIFN/RBV
generally seem to have similar efﬁcacy to the ﬁrst wave new
AVT [17,18,22,24,26,28] although results with polymerase and
NS5a inhibitors (plus PegIFN/RBV) have increased SVRs up to
90% [19,21,23,25,26,29–31]. There is preliminary data that com-
binations of DAAs and PegIFN/RBV (so called quadruple therapy)
may have very high SVRs (>95%) [20,27,28,32].
Despite some enthusiasm for the best of the second wave
therapies, the third ‘‘wave’’ is likely to be the most signiﬁcant
and certainly the most exciting. This wave aims to replace inter-
feron altogether. The regimes use DAAs in combination without
interferon but sometimes with ribavirin e.g., a HCV NS5A poly-
merase inhibitor combined with second (or third generation)
NS3/4 protease inhibitors or an NS5A inhibitor [31–36]. One
exciting regime just used a nucleoside polymerase inhibitor plus
ribavirin [33]. This resulted in SVRs of 90–100% in treatment
naïve G2/3 patients requiring only 3 months of therapy with no
recorded toxicity. However, the same regime applied to genotype
1 patients who were previously null responders to PegIFN/RBV,
however, it seems disappointing with signiﬁcant relapse rates
[34]. An alternative regime of an NS5A inhibitor plus a polymer-
ase inhibitor, given for only 3 months led to an SVR of 90% in
patients with HCV G1b who had previously been null responders
to interferon [35]. It is generally thought that G1b is more sensi-
tive to the DAAs and is associated with an enhanced resistance
barrier. It is unclear whether ribavirin will remain an important
agent in these new treatment regimens [20,28,37].
In summary, these ‘‘third wave’’ regimes are aimed to be non-
genotype speciﬁc, taken once per day, have limited toxicities and
taken for a short duration (as short as 3 months). As mentioned,
SVR is expected to be in 90% range. It should be noted, however,
that many of these studies are at the proof of concept stage and
have only been reported in small numbers of patients. Further-
more, these agents have not yet been used in patients with
advanced liver disease and portal hypertension (see Table 2).
Currently, there is no data on any of these ﬁrst, second or third
‘‘wave’’ AVT regimes in the setting of liver transplantation. Thus,12 vol. 57 j 1361–1367
Table 1. The three ‘‘waves’’ of direct antiviral agents for HCV infection.#
Wave Predicted dates in 
practice
Regimen Genotype Therapy duration 
(mo)
SVR 
(%)
Side effects
1st 2011-2014 B + P + R* 1 6-12 65-70 ++
T + P + R° 1 6-12 65-70 ++
2nd 2013-2015 P.I + P + R 1 6 65-80 ± → +
Pol.I + P + R pan 6 60-90 ± → +
P.I/Pol.I + NS5AI + 
P + R
pan 6 90 ± → +
3rd 2014- Pol.I + R pan 3-6 90 ±
Pol.I + P.I ± R pan 3-6 90 ±
NS5AI + P.I + Pol.I pan 3-6 90 ±
#Treatment naïve patients.
⁄Ribavirin; B, boceprevir.
T, telaprevir.
Pi, protease inhibitors; Pol I, polymerase inhibitor; NS5AI, NS5A inhibitor.
Table 2. Some issues beyond ‘‘proof of concept studies for’’ interferon-free
therapies.
• SVRs in non-G2/G3, non- 1b patients
• Genotype 
• Duration of therapy in non-G2/G3, non-1b patients
• Duration of therapy in transplant patients (pre and post)
• Side effect  in cirrhotic patients with portal  hypertension
• SVRs in cirrhotic patients with portal  hypertension
specificity
profile
Frontiers in Liver Transplantationthe following discussion is largely speculative and deductive. It
will be interesting to come back in the years ahead as new data
arise. Hopefully the comments below will have some relevance
but that cannot be guaranteed!Use of the new therapies pretransplant (Table 3)
Triple therapy with either telaprevir or boceprevir
The ﬁrst issue is that these agents are only aimed at HCV G1. The
second issue is that many of these patients will already have
failed PegIFN-based AVT. Thus, it will remain important (as
now) to classify patients into those who have previously relapsed
versus those who have been non-responders. Patients without
cirrhosis who have relapsed may have up to an 85% SVR to these
new regimes whilst non-responders may be as low as 30%
[13,14]. However, previously interferon-treated patients with
well-compensated cirrhosis and signiﬁcant portal hypertensionTable 3. Potential issues with 1st ‘‘wave’’ therapies in the transplant setting.
Pretransplant • Only G1 patients
• Overall SVR may only be
• Many patients previous n
• Toxicity  may be h
Post-transplant • Only G1 patients
• Drug-drug interactions (t
• Overall SVR only 40%
profile
1362 Journal of Hepatology 2012are likely to have much lower SVRs. There is evidence that IL28
polymorphism testing still has a role in treating patients with
telaprevir or boceprevir [38]. Perhaps this will be even more
important in treating patients with advanced disease in order
to maximize SVRs.
The third issue is: what is the expected SVR in naïve subjects
with cirrhosis and portal hypertension being treated with these
agents? Although it is tempting to use these agents (given the
increased SVR) it is not clear what that SVR will be. If we assume
a 50% improvement on the current 15–20% SVR in patients with
genotype 1 infection then the likely SVR will still only be in the
vicinity of 20–30%. That assumes that the treatment withdrawal
rate will be the same as the current standard of care therapies.
However, that is unlikely.
The fourth issue is the likely increased side effect proﬁle when
treating such patients. A recent study in abstract form gives some
data on the real time use (non-clinical trial) of these regimes in
patients with cirrhosis who had failed previous interferon thera-
pies [39]. Although there is no SVR data, safety data for both tela-
previr and boceprevir were given for the ﬁrst 16 weeks of therapy.
In these patients, 19–28% had varices, 29–48% were relapsers, the
mean serum albumin was about 40 g/dl, and the mean platelet
count was 150,000. Thus although some of these may have been
transplant candidates the vast majority were not. Despite this, 4
deaths occurred in 362 patients (1.3%) in the ﬁrst 16 weeks, and
6–12% had therapy discontinued due to serious adverse events.
Erythropoietin was used in about 50% of patients and blood trans-
fusion was required in between 6–18% of patients.
This data does raise caution about the safety proﬁle in much
sicker patients. Concern with the skin rash in patients with portal
hypertension is even greater than in non-cirrhotic patients. These 20-25% in G1 patients
on-responders to PegIFN/RBV, SVR even lower
igher
acrolimus, cyclosporin, TOR inhibitors ↑ 5x)
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patients have signiﬁcant defects in neutrophil function [40] and sec-
ondary skin infections (particularly Staphylococcus) could prove fatal.
The ﬁnal issue is the emergence of anti-protease resistance
strains of HCV in pretransplant patients [41]. This will be a par-
ticular issue in previous interferon non-responders where, if
these new therapies are continued for any length of time, then
resistant strains will be ampliﬁed. Thus stopping rules need to
be strictly observed in these patients. The implication here in
transplant patients will be the effect of access to future protease
inhibitor-based therapies if signiﬁcant resistance is detected. If
signiﬁcant resistance emerges, patients with mild disease can
probably wait until better agents emerge (third wave). However,
transplant candidates may require more urgent access to newer
therapies but will almost certainly not be suitable for antipro-
tease-based therapies that have cross-resistance proﬁles with
boceprevir and telaprevir.
I would conclude that the signiﬁcant use of these ﬁrst wave
therapies in pretransplant waiting list patients will be problem-
atic and perhaps not worth the effort or the risk. As now, such
therapies will probably be conﬁned to Child A patients with
hepatocellular cancer. Already much discussion has been had
on whether to ‘‘by pass’’ these agents in this patient group and
head straight to second wave or third wave agents.
Triple/quadruple therapy with next generation AVT
If boceprevir and telaprevir are likely to have minimal impact
then what about the next wave of AVT? As mentioned, the major
difference between these agents and boceprevir or telaprevir is
the ease of administration (daily) and less genotype speciﬁcity.
Side effects still occur (although different) and the SVR seems
about the same in next generation P.Is plus PegIFN/RBV. It would
seem that the main advantage with these agents would be in
patients infected with genotype 2/3 virus where the P.I. had
expended genotype speciﬁcity. Currently, such patient’s pretrans-
plant may have an SVR of up to 35%. Extrapolating that these sec-
ond wave agents would increase SVR by 50% then perhaps we
could expect SVRs of about 45% or even 50% pretransplant. Thus
it may be tempting to use them. However, the key once again will
probably be tolerability. The widespread use in patients infected
with genotype 1 HCV would seem to have similar caveats to the
use of boceprevir and telaprevir. As mentioned, patients infected
with genotype 1 HCV who failed these therapies would not be
suitable/eligible for second wave protease inhibitor therapies
with cross-resistance proﬁles.
As previously mentioned, polymerase inhibitors or NS5A
inhibitors plus PegIFN/RBV, however, may have a signiﬁcant
impact re SVRs. Tolerability will mainly revolve around the Peg-
IFN/RBV combination as now.
Non-interferon-based therapy
This seems to be most likely a breakthrough and a paradigm shift
for patients awaiting liver transplantation. The goal of these
approaches is fourfold. (1) To achieve 90% SVR, (2) to have mini-
mal side effects, (3) to be pan genotypic, and (4) to be of short
duration (maximum 6 months). All of these seem potentially
achievable. 90–100% SVRs have already been reported in treat-
ment naïve patients infected with genotype 2/3 HCV using just
polymerase inhibitor and ribavirin for 3 months [33]. Although
initially tested in patients with genotype 2/3 HCV, this regimeJournal of Hepatology 2012is thought to be pan genotypic. Use of an NS5A inhibitor + next
generation protease inhibitor in patients with genotype Ib HCV
(who were previously null responders to interferon) also resulted
in a 90% SVR [35].
It is expected that an increasing number of combinations will
emerge in the next 1–2 years and perhaps be in clinical practice
within 5 years ([16], Table 1). If such predictions are true, then
the whole landscape of human liver transplantation will change
dramatically, perhaps in a similar fashion to the change in out-
comes that occurred in patients with chronic hepatitis B infection
awaiting transplantation in the mid to late 1990s, with the intro-
duction of lamivudine and adefovir [42].
The ﬁrst change would be that almost all patients awaiting
liver transplantation would be rendered PCR negative and effec-
tively cured of HCV. This would include patients with hepatocel-
lular cancer and low MELD scores. These patients based on
current paradigms could be treated for 3–6 months with AVT
and proceed to transplant within 3–6 months with the likelihood
of no HCV recurrence.
The second group would be those who have end stage decom-
pensated liver disease. Currently, it seems very unlikely that such
patients will be treated with boceprevir or teleprevir or even sec-
ond wave approaches, as both require PegIFN/RBV. In the pre-
transplant context, however, I would dispute the automatic
conclusion that obtaining an SVR in such decompensated patients
will necessarily avoid liver transplantation in a similar fashion to
that seen in HBV. Firstly, there are HBV patients who do not
recover and die, despite successful control of HBV replication
[43]. MELD scores of >25 characterize these patients. Secondly,
decompensation in chronic HBV infection is often due to ﬂair of
HBV replication superimposed on cirrhosis. In other words, HBV
patients usually do not just slip slowly into decompensation
and overt liver failure. In contrast, that is exactly what patients
with end stage HCV cirrhosis do, often precipitated by infection
or bleeding. Although we would all hope that eliminating HCV
at this stage would revert such patients to a compensated state,
this remains to be established. It is worthy to note that data
are lacking on signiﬁcant improvement in MELD scores in
patients currently on waiting lists undergoing SVR with current
standard of care with PegIFN/RBV. At best, some of these patients
stabilize and even if improvement is seen, it happens slowly
(Xavier Forns, Barcelona; Greg Everson, Colorado personal com-
munications). It could be argued that non-interferon-based
regimes will not have the catabolic effects in these patients that
is induced by interferon and hence improvement will be expected
and happen over a shorter time frame. This remains an interest-
ing point of discussion that the future will resolve. In addition to
these issues is the recent provocative ﬁnding that patients with
HCV infection still have increased liver-related morbidity and
mortality compared to the general population, despite obtaining
an SVR [44]. If this is true then liver transplantation for patients
with decompensated HCV and an SVR may still be required.
To conclude, third wave therapies are likely to dramatically
change the landscape. It is predicted that these therapies deliv-
ered pretransplant will prevent HCV recurrence post-transplant.
Treatment duration may differ depending on genotype and previ-
ous responses to interferon. Patients with HCC and HCV will still
require transplantation. It remains unclear, however, what per-
centage of patients with decompensated advanced liver failure
and high MELD scores will be ‘‘rescued’’ thus avoiding transplant
altogether. Watch this space. . .vol. 57 j 1361–1367 1363
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Could new therapies prevent HCV infection of the allograft at
time of transplant?
New anti HCV monoclonal antibodies
Current approaches using such interventions have not been suc-
cessful. However, a more recent study using a human monoclonal
antibody against HCV E2 suppressed viral replication during the
7 days of therapy immediately post-transplant [44]. Thus, this
approach may still have some merit.
What about blocking uptake at receptor level?
The identiﬁcation of Claudin1, CD81, Occludin, and Scavenger
receptor class B1 (SR-B1) as a network of receptors involved in
HCV uptake does raise the possibility that blocking Mabs aimed at
HCV binding sites could prevent HCV uptake into the liver at the
time of transplantation [45–47]. Currently, however, no such
in vivo data exist although a recent study in humanized mice has
shown that novelmonoclonal antibodies against SR-B1 are effective
not only in preventing uptake but also cell – cell spread of HCV [48].
What about blocking uptake at the tyrosine kinase level?
Recent data indicate that the tyrosine kinase system feeding off
the epidermal growth factor receptor is crucial in the complete
uptake of HCV into hepatocytes [49].
Such inhibitors currently exist in oncological practice and
could theoretically be applied intraoperatively and immediately
post surgery to block uptake of HCV at the time of allograft
implantation. The toxicity of such molecules administered for
short periods of time may be minimal. Perhaps such agents could
be used in combination with neutralizing mAbs and blocking
mAbs aimed at HCV receptors. It is unclear what duration of ther-
apy post-liver transplantation would be required but it seems
likely it would be >1 week.
In conclusion, such approaches outlined in this section are
intellectually appealing but currently it is not clear how practical
they would be. They may be unnecessary if third wave DAAs are
very successful.Use of new therapies post-liver transplant (Table 4)
Triple therapies with either telaprevir/boceprevir
As mentioned, current treatments with PegIFN/RBV yield about a
20–30% SVR (G1) in the stable post-transplant setting. The use of
telaprevir or boceprevir in these patients may increase SVR to
about 40% (G1). Thus, there is currently great interest in introduc-Table 4. Observations in initial assessment of triple therapy for HCV post-liver trans
• Side effects, particularly  anemia very common (needing 
•  Ribavirin dose reduction common
• Many patients switched to cyclosporine-based immunosuppression
• Drug-drug interactions seem to be manageable 
• Mortality observed if patients treated at advanced stages of recurre
significant
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founding issues, however, exist.
Firstly, drug–drug interactions [50–52]. Boceprevir and tela-
previr are metabolized via the cytochrome P450 3a system and
compete with cyclosporine, tacrolimus, evolimus, and rapamycin
for metabolism. Emerging data suggest that the area under the
curve for these immunosuppressive agents is dramatically
increased when given with telaprevir or boceprevir. Increases of
up to 70-fold have been observed with tacrolimus and 5-fold with
cyclosporine. This will make boceprevir or telaprevir difﬁcult to
use but not impossible. Dose adjustments of these immunosup-
pressive drugs in a similar fashion to those required with some
HART regimes in HIV infected transplant patients will be required.
Secondly, the side effect proﬁle in immunosuppressed
patients may be exaggerated and thirdly, the issue of previous
non-responsiveness to interferon and potential protease inhibitor
resistance may signiﬁcantly decrease efﬁcacy. Lastly, optimal
durations of therapy will need to be established.
Despite these concerns, there are now several reports in
abstract form on the use of either of these two agents in the
post-transplant period. [53–61]. These reports usually only
include a small number of patients although when presented at
various meetings the numbers have been greater. In essence, sev-
eral themes have emerged (Table 4). Firstly, there is little or no
SVR data, Secondly, drug interactions seemed to have been well
managed although very high levels of tacrolimus have occasion-
ally been seen. Thirdly, many users have converted their patients
to cyclosporine-based immunosuppression before commencing
AVT. Fourthly, side effects and dose reduction of ribavirin are
common. In some studies, treating cholestatic hepatitis has not
always been successful due to the introduction of triple ther-
apy-based AVT at very late stages of disease. Mortality has been
reported in such patients. A recent report, however, does show
an SVR can be achieved in cholestatic hepatitis [62].Triple/quadruple therapies with next generation P.Is/polymerase
inhibitors
The issues here are similar to those raised with boceprevir and
telaprevir although the ease of use and increased genotype sus-
ceptibility and increase SVR in non-protease-based therapies
may encourage early introduction. Furthermore, some P.Is have
been developed that are not metabolized via the cytochrome
P450 system and thus may be easier to use with current immu-
nosuppressive drugs [63].
Non-interferon-based therapies
As pretransplant, there is great hope for the future here. Apart for
the potential for marked increased efﬁcacy, the lack of toxicityplant [53–62].
erythropoietin and/or blood transfusion)
 before AVT
nce (particularly advanced cholestatic HCV)
vol. 57 j 1361–1367
Table 5. Non-interferon-based therapies. (A) Potential beneﬁts of 3rd non-interferon-based therapies in liver transplant. (B) Limitations regarding non-interferon-based
therapies in liver transplant.
Pretransplant • SVR pretransplant will abolish post-transplant HCV recurrence  
• SVR pretransplant will lead to  improvement of MELD scores and remove the
need for transplant in non-HCC patients with MELD <25
Post-transplant • Could be used early after transplant
• SVR rates very high
• Reversal of established disease including cholestatic HCV
• HCC patients will still require transplant
• SVR in patients with MELD <25 may not abolish need for transplant
A
B
significant
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best of these therapies to be introduced very early post-trans-
plant in patients who remain viremic at transplant (in a similar
fashion to HBV antivirals). This would result in viral control from
the time of transplant. It should, however, be pointed out that if
these third wave agents cure HCV pretransplant, then no AVT at
all will be required post-transplant! (see Table 5).
It is known that HCV replication occurs at the time of allograft
implantation but for the ﬁrst month post-transplant this rarely
results in allograft pathology [64,65]. Thus, if viral control during
this time and elimination within 3 months are achieved, it is
likely that these type of agents could very well eliminate HCV
related allograft pathology. This would be the holy grail of using
such therapies if required early post-transplant. It would be pre-
sumed that very early use post-transplant would be better toler-
ated in ribavirin-free regimes. A challenge here would be the
question concerning the duration of therapies post-transplant
setting. If 3-month duration emerges as sufﬁcient in the non-
transplant setting, the post-transplant situation may require
longer duration in the setting of immunosuppression. This will
need to be studied. Even if early viral control and or elimination
does not become the optimal strategy, it is likely that the use of
these regimes will achieve a 90% SVR at later stages of infection,
once again duration of therapy in the post later post-transplant
will need to be clariﬁed. Using such approaches should com-
pletely eliminate cholestatic HCV and even if such cases do occur,
it would be hoped that the severe allograft dysfunction associ-
ated with a form of HCV infection could be reversed (although
that cannot be totally assured).Predictions of the (near) future
It seems likely that the new age of AVT will radically improve
outcomes for patients with HCV infection in the setting of liver
transplantation. Currently, this is a hope as there is no data to
support this claim. It is a strong intellectual prediction based
on non-transplant data. It may be only the introduction of the
third wave of non-interferon-based therapies that will achieve
this routinely in the pre and post-transplant setting. Whether
immediate uptake of the ﬁrst and second wave therapies is war-
ranted remains debatable and whether neutralization of the virus
at the time of transplant is worth studying may depend on how
successful the third wave of HCV therapeutics is in the transplant
setting. In the long-run, successful use of the third wave will
abolish HCV infection even in advanced disease well before trans-
plant is required. This will leave only HCC patients and patientsJournal of Hepatology 2012with advanced liver failure that slip through the net and present
late requiring transplantation. Furthermore, such patients will
not require post-transplant AVT or, if they do, it will likely be
for short periods of time.
Whatever the exact outcomes, exciting, and challenging times
lie ahead.
As examples of questions that will be answered quite soon,
the reader is invited to answer yes or no to the following, and
revisit your answers in 3–5 years from now:
1. The introduction of boceprevir or telaprevir will signiﬁcantly
alter outcomes for patients on the transplant waiting list?
(? No)
2. New second generation protease inhibitors will signiﬁcantly
alter outcomes for patients on the waiting list? (? Maybe)
3. Blocking HCV uptake at the time of transplant will become
part of future anti HCV strategies? (? No)
4. Non-interferon-based therapies will lead to reversal of hepatic
decompensation in the pre transplant setting? (? Maybe)
5. Non-interferon regimes will be used pretransplantation with
subsequent elimination of HCV post-transplant in virtually
all patients? (? Yes+++)
6. Non-interferon regimes will only be required for <6 months in
the post-transplant setting? (? Maybe)
7. In 10 years time, the only HCV patients requiring transplanta-
tion will be those with HCC? (? Yes)Conﬂicts of interest
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